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ABSTRACT
As a behavioural addiction, gambling disorder (GD) provides an opportunity to characterize addictive processes without
the potentially confounding effects of chronic excessive drug and alcohol exposure. Impulsivity is an established precur-
sor to such addictive behaviours, and GD is associated with greater impulsivity. There is also evidence of GABAergic dys-
regulation in substance addiction and in impulsivity. This study therefore investigated GABAA receptor availability in 15
individuals with GD and 19 healthy volunteers (HV) using [11C]Ro15-4513, a relatively selective α5 benzodiazepine re-
ceptor PET tracer and its relationship with impulsivity. We found signiﬁcantly higher [11C]Ro15-4513 total distribution
volume (VT) in the right hippocampus in the GD group compared with HV. We found higher levels of the ‘Negative
Urgency’ construct of impulsivity in GD, and these were positively associated with higher [11C]Ro15-4513 VT in the
amygdala in the GD group; no such signiﬁcant correlations were evident in the HV group. These results contrast with
reduced binding of GABAergic PET ligands described previously in alcohol and opiate addiction and add to growing ev-
idence for distinctions in the neuropharmacology between substance and behavioural addictions. These results provide
the ﬁrst characterization of GABAA receptors in GDwith [
11C]Ro15-4513 PETand show greater α5 receptor availability
and positive correlations with trait impulsivity. This GABAergic dysregulation is potential target for treatment.
Keywords GABA system, gambling disorder, [11C]Ro15-4513 PET.
Correspondence to: Anne R Lingford-Hughes, Centre for Neuropsychopharmacology, Division of Brain Sciences, Faculty of Medicine, Imperial College
London, 160 Du Cane Road, London W12 0NN, UK. E-mail: anne.lingford-hughes@imperial.ac.uk
INTRODUCTION
There is considerable overlap between gambling disorder
(GD) (previously termed pathological gambling) with
drug and alcohol addiction with regard to clinical phe-
nomenology and treatment, comorbidity, heritability
and neurobiological proﬁle (Clark 2014; Clark and
Limbrick-Oldﬁeld 2013). Predicated on such evidence,
this condition was recently reclassiﬁed from an ‘impulse
control disorder’ in DSM-IV to the ‘substance-related
and addictive disorders’ in DSM-5 (Clark 2014). As a
behavioural addiction, GD provides an opportunity to
characterize addictive processes without the potentially
confounding effects of chronic excessive drug/alcohol
exposure. Compared with drug or alcohol addiction, little
is known about the neuropharmacology of GD, and a
better characterization of its neurobiology will inform
developments in the prevention and treatment of both
substance and behavioural addictions.
Recent studies using positron emission tomography
(PET) to directly assess the dopamine and opioid systems
in GD have demonstrated some unexpected differences to†These authors contributed equally to this work.
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established ﬁndings in substance addictions. For instance,
in contrast to studies in cocaine and alcohol addiction,
[11C]raclopride and [11C]-(+)-PHNO PET revealed no dif-
ferences in dopamine receptor DRD2/3 availability and
greater stimulant-induced dopamine release in individ-
uals with GD compared with healthy volunteers (HV;
Albein-Urios et al. 2012a,2012b; Boileau et al. 2013;
Boileau et al. 2014). A key modulator of the dopaminer-
gic system is the mu opioid receptor (MOR), and opiate
receptor antagonists have some efﬁcacy in treating GD.
Higher MOR availability has been reported in studies by
using [11C]carfentanil or [11C]diprenorphine PET in
cocaine, opiate and alcohol addiction (Gorelick et al.
2005; Heinz et al. 2005; Williams et al. 2007; Williams
et al. 2009). However, we recently reported no difference
in [11C]carfentanil binding in individuals with GD (Mick
et al. 2015). Thus, in vivo PET imaging studies of neuro-
pharmacology suggest that GD shows important differ-
ences to substance addiction.
The GABAergic system is another key modulator of
mesolimbic dopaminergic processes but has received
scant attention in the context of addictions (Hayes et al.
2014). With the [11C]Ro15-4513 PET radiotracer, which
is relatively selective for the α5 subtype of the benzodiaz-
epine receptor, we observed in alcohol and in heroin
addiction lower levels of limbic [11C]Ro15 4513 binding,
particularly in the nucleus accumbens (NAc) and right
hippocampus (Lingford-Hughes et al. 2016; Lingford-
Hughes et al. 2012a). We have also shown that [11C]
Ro15 4513 binding was higher in participants with a
history of tobacco smoking (Stokes et al. 2013) .
With regard to gambling, Nussbaum et al. (2011) pro-
posed that GABAergic modulation of opioid release in the
brain reward system may be important to the ‘rush’ expe-
rienced by gamblers in response to major jackpots and
that differences in this modulation could distinguish indi-
viduals with GD from non-dependent gamblers. There is
limited further evidence regarding the GABAergic system
in individuals with GD, with some inconsistent evidence
of greater GABA concentrations measured in the CSF in
GD (Nordin and Sjodin 2007; Roy et al. 1989). These
observations, as well as the growing use of GABAergic
medication such as baclofen and topiramate to treat
addiction, indicate that it is timely and important to char-
acterize the GABAA receptor system in GD (Lingford-
Hughes et al. 2012b).
A major feature common to gambling and substance-
related disorders is impaired impulse control, which may
be fundamental to both the development and mainte-
nance of addictive disorders (Bechara 2005; Lawrence
et al. 2009; Verdejo-Garcia et al. 2008). We have previ-
ously shown that Negative Urgency (NU) derived from
the UPPS-P impulsivity scale is related to dopamine
D2/3 receptor availability in GD (Clark et al. 2012) and
also to MOR availability (Mick et al. 2015). As the main
inhibitory neurotransmitter in the human brain, the role
of GABAergic functioning in impulsivity is attracting
attention with growing preclinical evidence supporting
its involvement (Hayes et al. 2014). For instance, a GABA
agonist and antagonist in the prefrontal cortex of rats
increased and reduced, respectively, impulsive responses
in the 5-choice serial reaction time task (Murphy et al.
2012; Paine et al. 2011). GABAA receptor binding is
lower in the anterior cingulate cortex of high-impulsive
rats compared with low-impulsive rats and is inversely
correlated with impulsive responding (Jupp et al. 2013).
Caprioli et al. reported increased impulsive behaviour in
rats following a reduction in glutamate decarboxylase
65/67, an enzyme responsible for the decarboxylation
of glutamate to GABA, gene expression in the NAc core
(Caprioli et al. 2014).
In this study, we therefore used [11C]Ro15-4513 PET
to measure GABAA receptor availability in GD and its
relationship with impulsivity. Based on our previous stud-
ies showing lower [11C]Ro15-4513 binding in the NAc in
both alcohol and in opiate addiction, we hypothesized
that GD would similarly be associated with lower levels
in the NAc. In addition, based on the preclinical evidence,
we hypothesized that impulsivity, speciﬁcally the NU trait,
in GD would be associated with higher [11C]Ro15-4513
binding; we have shown that [11C]Ro15-4513 is sensitive
to GABA and low levels of GABA are associated with
higher [11C]Ro15-4513 binding (Stokes et al. 2014).
MATERIALS AND METHODS
Participants
Study participants comprised of 15 male treatment-
seeking individuals with GD (DSM-IV) (34.8±7.5 years,
four current and two ex-smokers (mean± standard devi-
ation (SD)) and 19 male age-matched HV (31.7
±7.5 years, six current and three ex-smokers). Individ-
uals with GD were recruited from the National Problem
Gambling Clinic, Central North West London NHS Foun-
dation Trust, UK, and participated in the study either
before (n=7) or during (n=8) their 8-week programme
of cognitive–behavioural therapy. HV were recruited by
advertisements in daily newspapers or from our database.
Written informed consent was obtained before participa-
tion in the study, which was approved by West London
Research Ethics Committee and the Administration of
Radioactive Substances Advisory Committee, UK.
Following a detailed telephone eligibility interview,
participants attended a screening visit to assess their
current and previous medical and psychiatric health.
Disordered gambling was assessed with the
Massachusetts Gambling Screen (6.7±1.9; a score of 5
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or more indicates GD) and the Problem Gambling
Severity Index (16.9±3.5; a score of 8 or above indicates
disordered gambling). All individuals with GD had a
recent history of active gambling with length of absti-
nence ranging from 3 to 158 days (63±49 days). HV
had no current or past history of psychiatric disorders
(ICD-10 or DSM-IVAxis I diagnostic criteria). As depres-
sion and anxiety disorders are common comorbidities in
GD, a history of these was permitted, but not a current
depression or anxiety disorder. Past recreational drug
use was allowed (>10 times in lifetime but never met
criteria for abuse or dependence: seven HV: ﬁve cannabis,
one cannabis and stimulants and one cannabis, halluci-
nogens and sedatives; four GD: two cannabis and two
cannabis, stimulants and cocaine), but abstinence from
illicit drugs 2weeks before and during study participation
was required. Current or past diagnosis of substance
dependence, except nicotine, was an exclusion criterion
for both groups. Participants were asked not to drink
more than 21 UK units of alcohol (166 g) per week
2weeks before and during the study. Urine drug
screens (for cocaine, amphetamine, methamphetamine,
morphine, methadone, benzodiazepines and tetrahydro-
cannabinol) and alcohol breath analyses were performed
at screening and PET scanning days. Cigarette smoking
was not allowed 1hour prior to each magnetic resonance
(MR) or PET scan. All participants had laboratory
(haematology, clinical chemistry and clotting
parameters) within normal range. None of the partici-
pants took regular medication.
Depressive symptoms were measured by using the
Beck Depression Inventory and anxiety with the
Spielberger State/Trait Inventory. Tobacco use was evalu-
ated in the smokers with the Fagerstrom Test for Nicotine
Dependence. To assess impulsivity, participants completed
the UPPS-P Impulsive Behavior Scale (Cyders et al. 2007),
a 59 item self-report questionnaire with ﬁve subscales:
Negative Urgency (NU), Positive Urgency, Lack of Plan-
ning (LoP), Lack of Perseverance and Sensation Seeking.
MR and PET imaging
On the screening day, a structural magnetic resonance
imaging (MRI) was performed on a 3T MR scanner
(Magnetom Trio Syngo MR B13 Siemens 3 T; Siemens
AG, Medical Solutions), including a volumetric T1-
weighted magnetization-prepared rapid acquisition
gradient-echo sequence. All structural images were
reviewed by an experienced neuroradiologist for unex-
pected ﬁndings of clinical signiﬁcance and structural var-
iation that might affect quantitative image analysis, and
none were observed. Participants also completed a func-
tional MRI battery (Paterson et al. 2015) and performed
a neurocognitive assessment whose results will be
described elsewhere.
For the [11C]Ro15-4513 PET scan, we followed our
previous protocol (Lingford-Hughes et al. 2012a). Brieﬂy,
each participant underwent a 90-minute [11C]Ro15-
4513 PET acquisition. PET data were reconstructed into
23 frames (4×15, 4×60, 2×150, 10×300 and
3×600 seconds) and corrected for head motion by using
normalized mutual information rigid-body registration of
each frame realignment to frame 16. A hierarchical
probabilistic atlas of 119 regions (Tziortzi et al. 2014)
was non-rigidly registered to PET space by using reverse
deformation parameters derived from the normalization
of the coregistered structural MRI to a standard template.
Atlas ﬁts were checked visually, and PET dynamic data
were sampled in each region of interest (ROI) to generate
time-activity curves, combining left and right ROIs to
generate single time-activity curves where laterality was
not hypothesized, i.e. in amygdala and orbitofrontal cor-
tex (OFC). A parent plasma input function was derived
by calibrating the continuous online blood counts to dis-
crete samples and correcting for plasma fraction and
radiolabelled metabolites collected at intervals through-
out the scan. The [11C]Ro15-4513 VT in each ROI could
then be quantiﬁed by using a 2-tissue-compartmental
model. This was shown, by parsimony criteria, to describe
appropriately the ligand kinetics in the range of ROIs con-
sidered (Myers et al. 2016a). In this dataset, spectral
analysis to partition this signal was not applied since we
have shown the total VT to represent robustly α5 subtype
binding (Myers et al. 2016a; Myers et al. 2012). All image
and kinetic analysis procedures were carried out by using
MIAKATTM (Imanova Ltd, UK).
Statistical analysis
Demographic differences between groups, and injected
mass/activity, were analysed by using independent-
samples t-tests (two-tailed). An omnibus mixed-model
ANCOVA tested [11C]Ro15-4513 VT as a function of
ROI (four levels) and Group (HV and GD) including age
and smoking as covariates. Results are presented as
mean+SD. Correlations between VT values and clinical
variables were performed by using Spearman's rank
correlation coefﬁcients.
Based upon our previous ﬁndings in alcohol and opi-
ate dependence for the [11C]Ro15-4513 PET analysis,
we selected right hippocampus and NAc as a priori ROIs,
and we chose two additional a priori ROIs based upon
their established role in impulse control: OFC and amyg-
dala (Goldstein and Volkow 2002; Jentsch and Taylor
1999; Ko et al. 2015; Nikolova et al. 2016). As previous
work (Clark et al. 2012; Michalczuk et al. 2011) has
shown that NU, as a mood-related subgroup of
GABA dysregulation in GD 3
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impulsivity, is most strongly associated with GD, we chose
to test for correlations between UPPS-P NU and a priori
selected brain regions. Correlations were considered sig-
niﬁcant at p<0.05, and for the group comparisons, if
ROIs are to be treated as independent, multiple compari-
son correction adjusts the signiﬁcance value to
p<0.0125.
RESULTS
Participants' characteristics
Demographic, clinical, and impulsivity data are summa-
rized in Table 1. There were no differences in age, intelli-
gence quotient, smoking status or amount of alcohol
consumed per week. Individuals with GD had greater
levels of depression (Beck Depression Inventory:
p=0.013) and anxiety [Spielberger Trait Anxiety Inven-
tory (STAI): p=0.001; Spielberger State Anxiety Inven-
tory (SSAI): p=0.014] and Alcohol Use Disorders
Identiﬁcation Test (AUDIT) score (p=0.037) than HV, al-
though none of the participants reached a clinically sig-
niﬁcant threshold in either group.
PET measures
There were no signiﬁcant differences (p>0.05) between
the groups for injected [11C]Ro15-4513 mass HV: 2.98
±1.06μg versus GD: 3.19±1.24μg nor for injected ra-
dioactivity HV: 352±77MBq versus GD 356±90MBq.
The omnibus ANCOVA including age and smoking
(Fagerstrom Test for Nicotine Dependence) for the a priori
regions revealed a signiﬁcant main effect of Group
(F1,28 =6.1, p=0.020), with greater mean VT in individ-
uals with GD compared with HV. This was driven by sig-
niﬁcant group differences in the [11C]Ro15-4513 total
distribution volume (VT) in the right hippocampus [t
(32) =2.7; p=0.011], which survives Bonferroni correc-
tion for multiple comparisons (Table 2). We did not show
any signiﬁcant difference in the NAc, OFC or amygdala
(p>0.05). There was also a signiﬁcant main effect of
smoking (F1,28 =4.8, p=0.037), such that Fagerstrom
scores correlated negatively with mean VT across the four
ROIs (rs=0.36; p=0.041). In both groups, there was
no signiﬁcant correlation between Alcohol Use Disorders
Identiﬁcation Test scores and [11C]Ro15-4513 VT. There
was also no signiﬁcant correlation between ‘length of ab-
stinence’ and [11C]Ro15-4513 VT. There was no signiﬁ-
cant difference between those that had started and not
started their cognitive–behavioural treatment (p>0.05)
in [11C]Ro15-4513 VT in any of the a priori ROIs.
Relationship between PET measures, impulsivity and
anxiety
Individuals with GD showed signiﬁcantly higher impul-
sivity scores in UPPS-P NU (p<0.001) and LoP subscales
(p=0.028) compared with HV (Table 1). Non-parametric
correlations were run between [11C]Ro15-4513 VT and
UPPS-P NU and revealed in the GD group, signiﬁcant pos-
itive correlations in the amygdala (rs=0.67; p=0.006),
right hippocampus (rs=0.53; p=0.038) and NAc
(rs=0.57; p=0.034; Table 3) (Fig. 1). There were no
Table 1 Participants' characteristics, clinical and impulsivity measures, mean ± SD.
HV n=19 GD n=15 Signiﬁcance (two-tailed)
Age 31.7 ± 7.5 34.8 ± 7.5 0.245
IQ 114.0 ± 13.5 116.5 ± 12.2 0.502
CPGI 0.2 ± 0.5 16.9 ± 3.5 0.001*
Gambling abstinence (days) - 63.3 ± 50.0 -
AUDIT 4.2 ± 2.8 6.5 ± 3.5 0.037*
Alcohol (units/ week) 9.0 ± 8.0 12.5 ± 7.4 0.182
Current smoking status (smoker/ex-smoker) 6/3 4/2 0.957
FTND 1.0 ± 1.8 2.4 ± 2.3 0.266
Cigarettes (per day) 6.0 ± 5.8 5.0 ± 7.1 0.793
BDI 1.3 ± 2.8 4.9 ± 5.0 0.013*
STAI 31.0 ± 9.0 42.5 ± 9.9 0.001*
SSAI 26.0 ± 5.1 36.3 ± 13.8 0.014*
UPPS-P NU 21.7 ± 5.8 30.7 ± 6.2 0.001*
UPPS-P PU 20.7 ± 6.9 25.0 ± 8.0 0.130
UPPS-P LoP 20.2 ± 4.7 24.3 ± 5.6 0.028*
UPPS-P LoPe 18.2 ± 4.4 21.1 ± 4.8 0.076
UPPS-P SS 34.3 ± 8.1 33.3 ± 7.7 0.722
GD, individuals with gambling disorder; HV, healthy volunteers; AUDIT, Alcohol Use Disorders Identiﬁcation Test; BDI, Beck Depression Inventory; CPGI,
Canadian Problem Gambling Inventory; FTND, Fagerstrom Test for Nicotine Dependence; GUQ, Gambling Urges Questionnaire; NART, National Adult
Reading Test; SSAI, Spielberger State Anxiety Inventory; STAI, Spielberger Trait Anxiety Inventory. *Signiﬁcant difference between groups.
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signiﬁcant correlations in the HV group (p>0.05). The
differential relationship with NU in the two groups was
conﬁrmed statistically by using a generalized linear
model, which showed a signiﬁcant impulsivity × group
interaction in the amygdala (p=0.015). These interac-
tions were non-signiﬁcant for right hippocampus and
NAc (p>0.05). There were no signiﬁcant correlations
between [11C]Ro15-4513 VT in a priori ROIs and LoP in
either of the groups.
As anxiety scores were signiﬁcantly different in HV
and individuals with GD (STAI; p=0.001 and SSAI;
p=0.014) and anxiety is related to UPPS-P NU, we also
explored correlations between trait anxiety (STAI), state
anxiety (SSAI), NU and [11C]Ro15-4513 VT in the 4
ROIs. There was a signiﬁcant positive correlation be-
tween STAI and [11C]Ro15-4513 VT in the amygdala
(rs=0.51; p=0.05) in the GD group, which was the only
one that survived Bonferroni correction. After controlling
for anxiety, the association between UPPS-P NU and the
amygdala [11C]Ro15-4513 VT remained signiﬁcant
(rs=0.63; p=0.016). There were no signiﬁcant correla-
tions with trait anxiety in the HV group, and state anxi-
ety was not signiﬁcantly correlated with [11C]Ro15-4513
VT in either group.
DISCUSSION
We report here the ﬁrst study investigating GABAA recep-
tor availability in GD and show signiﬁcantly greater [11C]
Ro15-4513 VT in the right hippocampus of individuals
with GD and a positive relationship between [11C]Ro15-
4513 VT and impulsivity. Notably, our ﬁnding of higher
[11C]Ro15-4513 VT is in contrast to our previous ﬁnding
of lower levels of [11C]Ro15-4513 binding in the NAc in
alcohol and in opiate dependence and lower levels in
the hippocampus in alcohol dependence (Lingford-
Hughes et al. 2016; Lingford-Hughes et al. 2012a).
Higher [11C]Ro15-4513 binding reﬂects greater GABAA
receptor availability, which may be due to increased
receptor expression or, as a consequence of Ro15-4513
being an inverse agonist, lower endogenous GABA levels
(Stokes et al. 2014). We are unable to separate these
two mechanisms within our study. Nevertheless, our
[11C]Ro15-4513 PET studies show clear differences in
GABAA receptor availability between substance addic-
tions and a behavioural addiction with lower levels of
[11C]Ro15-4513 binding in both alcohol and opiate
addiction not apparent in GD (Lingford-Hughes et al.
2016; Lingford-Hughes et al. 2012a).
In our studies in substance dependence, signiﬁcantly
lower [11C]Ro15-4513 VT was found in the hippocampus
in alcohol dependence but not in opiate dependence. In
these studies, we used spectral analysis (Myers et al.
2012) to show that these ﬁndings in alcohol dependence
were driven by the α5 subtype rather than α1; this is
consistent with the high level of α5 subtype in the hippo-
campus and selectivity of [11C]Ro15-4513 PET (Lingford-
Hughes et al. 2016). In the current study in GD, [11C]
Table 2 Comparison between groups of [11C]Ro15-4513 VT in a priori deﬁned brain regions, mean ± SD.
HV n=19 GD n=15
Mean SD Mean SD Signiﬁcance (two-tailed)
Orbitofrontal cortex 6.99 ± 0.75 7.18 ± 0.87 0.563
Amygdala 7.44 ± 0.65 7.97 ± 0.87 0.058
Hippocampus R 7.44 ± 0.72 8.13 ± 0.74 0.011*
Nucleus accumbens 9.76 ± 0.72 9.95 ± 1.04 0.544
GD, individuals with gambling disorder; HV, healthy volunteers; L, left hemisphere; R, right hemisphere. HV: Amygdala n = 18; GD: N. Accumbens
n = 14. *Signiﬁcant at p< 0.05.
Table 3 Spearman's correlations between UPPS-P NU and [11C]Ro15-4513 VT in the GD and HV groups.
HV n=19 GD n=15
Correlation coefﬁcient Signiﬁcance (two-tailed) Correlation coefﬁcient Signiﬁcance (two-tailed)
Orbitofrontal cortex 0.08 0.731 0.51 0.052
Amygdala 0.00 0.990 0.67 0.006**
Hippocampus R 0.10 0.680 0.53 0.043*
Nucleus accumbens 0.46 0.050 0.57 0.034*
HV, healthy volunteers; GD, individuals with gambling disorder; L, left hemisphere; R, right hemisphere. HV: Amygdala n = 18; GD: nucleus accumbens
n = 14. *Signiﬁcant at p< 0.05. **Signiﬁcant at p< 0.01.
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Ro15-4513 VT in each ROI was quantiﬁed by using a 2-
tissue-compartmental model, which we have shown to
be suitable to describe the α5-subtype-speciﬁc signal of
[11C]Ro15-4513 in most ROIs (Myers et al. 2016a)
though the contribution of other subtypes in regions with
low GABAA α5 density, such as the cerebellum, should
also be considered.
We have previously reported higher [11C]Ro15-4513
VT in various brain regions including the hippocampus,
in HV smokers, which was particularly evident in ex-
smokers with levels in current smokers similar to non-
smokers (Stokes et al. 2013). However, these individuals
were not heavy smokers, and in the current study, the
amount of smoking was even lower so the majority were
not dependent smokers. Given there were only a few cur-
rent smokers, we are unable to explore further the impact
of smoking on [11C]Ro15-4513 VT binding in GD.
Consistent with previous work, we found higher im-
pulsivity scores in individuals with GD compared with
HV (Clark et al. 2012; Michalczuk et al. 2011). Preclin-
ical studies suggest that reductions in or lower levels of
GABA are associated with greater impulsivity (Boy
et al. 2011; Murphy et al. 2012; Paine et al. 2011).
We have previously shown that [11C]Ro15-4513 is sen-
sitive to GABA levels, and since it is an inverse benzo-
diazepine agonist, lower levels of GABA would be
associated with higher [11C]Ro15-4513 binding. Con-
sistent with our hypothesis that there would be a posi-
tive relationship between impulsivity and [11C]Ro15-
4513 VT, we found such a relationship in subcortical
limbic regions in GD but not in HV. The relationship be-
tween [11C]Ro15-4513 VT and ‘NU’ construct of impul-
sivity adds further support to the idea that mood-
related impulsivity is especially relevant to disordered
gambling (Clark et al. 2012; Nussbaum et al. 2011).
It is notable that we have found NU to be associated
with our PET studies of dopamine D2, MOR and now
GABA-A receptor in those with GD but not healthy
controls suggesting that dysregulation in these systems
has particular relevance to impulsivity in gambling
(Clark et al. 2012; Mick et al. 2015). Given the associ-
ation with NU, further exploration revealed a positive
relationship between trait anxiety and [11C]Ro15-
4513 VT in the amygdala in the GD group only. Nota-
bly, the positive correlation with [11C]Ro15-4513 VT
and NU in the amygdala remained signiﬁcant after con-
trolling for anxiety. The amygdala is a key region in-
volved in a number of processes such as emotional
processing, fear, reward valence and neuropsychiatric
disorders including addiction and anxiety (Elman et al.
2012; Janak and Tye 2015; van Holst et al. 2012).
However, evidence from neuroimaging studies using
non-speciﬁc benzodiazepine radiotracers [11C]ﬂumazenil
PET or [123I]iomazenil SPET about GABAA receptor
availability within the amygdala in relation to these
processes is limited and inconsistent. The most evidence
relates to anxiety where no relationship or negative
correlations have been reported in HV and both positive
and negative correlations in patients with anxiety
Figure 1 Signiﬁcantly positive correlations between Negative Ur-
gency impulsivity and [11C]Ro15-4513 VT in individuals with gambling
disorder
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disorders (Abadie et al. 1999; Esterlis et al. 2009;
Hasler et al. 2008; Lingford-Hughes et al. 1998).
Our ﬁnding of an association between impulsivity and
GABAA receptors in vivo in individuals with GD is consis-
tent with evidence from pharmacological challenges with
GABA modulating drugs such as benzodiazepines, which
suggest that increased GABAergic neurotransmission is
associated with impulsivity (Hayes et al. 2014). Other
studies in man have explored the relationship between
GABA levels assessed with magnetic resonance spectros-
copy. Whilst GABA measured this way is predominantly
metabolic in origin (Myers et al. 2014; Myers et al.
2016b), it is interesting that a lowered magnetic reso-
nance spectroscopy GABA signal ([GABA+]) in HV has
in some studies been associated with higher levels of im-
pulsivity. For instance, it has been shown that [GABA+]
levels in dorsolateral prefrontal regions negatively corre-
late with urgency impulsivity (Boy et al. 2011); low
[GABA+] in perigenual anterior cingulate cortex was as-
sociated with greater delay aversion on Cambridge gam-
bling task (Fujihara et al. 2015) and higher scores on
self-report Barratt Impulsiveness Scale-11 in one study
(Silveri et al. 2013) but not another (Janes et al. 2013).
Lower [GABA+] in the striatum is associated with poorer
impulse control in Go-NoGo task (Quetscher et al. 2015).
Such relationships add to the notion that modulating
GABA is a potential target for treatment of GD.
We acknowledge that the number of patients included
in this study is small. Based on our previous [11C]Ro15-
4513 studies in alcohol and opiate dependent partici-
pants, we expected to ﬁnd lower VT in the NAc. A post
hoc power calculation revealed that we would need more
than 150 additional [11C]Ro15-4513 PET scans in order
to be able to detect a statistically signiﬁcant group differ-
ence in the NAc. The power calculation was performed by
using the mean and SD data collected in our study, with
alpha=0.05, to show a difference with 80 percent
power. This number is beyond what is ethically accept-
able and feasible for a PET study, and we therefore did
not continue scanning.
In summary, we provide here the ﬁrst evidence of
GABAA dysregulation in individuals with GD with in-
creased [11C]Ro15-4513 VT in the right hippocampus.
This is different to substance dependence where we have
shown reduced [11C]Ro15-4513 VT in the NAc (Lingford-
Hughes et al. 2016; Lingford-Hughes et al. 2012a). As de-
scribed, GD was categorized in DSM-IV as an impulse
control disorder but based on shared clinical and
aetiological features is now classiﬁed as a behavioural ad-
diction in DSM-5. The current study adds to our and
other previous studies failing to show similar ﬁndings in
dopamine D2/3 receptor availability or mu opiate recep-
tor availability between GD and substance dependence
(Clark et al. 2012; Mick et al. 2015). Thus, our data
suggest that the view that, as a behavioural addiction,
the neuropharmacology of GD would be similar to sub-
stance addiction is now less certain. However, these dif-
ferences may reﬂect the impact of the chronic excessive
drug/alcohol exposure on the brain as opposed to the un-
derlying addictive processes themselves. On the other
hand, our PET studies and those of others all report a re-
lationship between impulsivity in GD with dopamine
D2/3, with MOR and with GABAA receptor availability
but not control groups. These associations suggest that
pharmacological modulation may result in reduced im-
pulsivity as an approach to treatment. Future studies
are necessary to further investigate the neurobiology of
this behavioural addiction in order to clearly address sim-
ilarities and distinctions given the critical role for
GABAergic function in addictive processes and its role
in neural regulation. The evidence, albeit limited, and
our data suggest that modulation of the GABA receptor
system is a potential target for the treatment of GD.
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